Sun Pharmaceutical Industries: Citi maintains a Buy on Sun Pharmaceutical Industries with a Target Price of ₹2180, citing strong ASCO 2026 data reinforcing UNLOXCYT’s competitive positioning in laCSCC, improved confidence on efficacy and tolerability, and supporting expectations of $400m+ peak sales by FY30.

 27 May 2026 08:56 AM

Sun Pharmaceutical Industries: Citi maintains a Buy on Sun Pharmaceutical Industries with a Target Price of ₹2180, citing strong ASCO 2026 data reinforcing UNLOXCYT’s competitive positioning in laCSCC, improved confidence on efficacy and tolerability, and supporting expectations of $400m+ peak sales by FY30.

Sun Pharma: Company Will Not Provide Margin Guidance, Expects West Asia War to Affect Future Quarters, and Noticing Increase in Logistics and Shipping Costs.

 25 May 2026 12:57 PM

Sun Pharma: Company Will Not Provide Margin Guidance, Expects West Asia War to Affect Future Quarters, and Noticing Increase in Logistics and Shipping Costs.

Sun Pharma: Expects Top-Line Growth In High Single Digits For FY27, Considering Current Regulatory And Economic Conditions. R&D Expenses Are Estimated To Be 6% To 7% Of Sales, With An Expected Effective Tax Rate Of 25% For Next Year And Beyond.

 25 May 2026 09:13 AM

Sun Pharma: Expects Top-Line Growth In High Single Digits For FY27, Considering Current Regulatory And Economic Conditions. R&D Expenses Are Estimated To Be 6% To 7% Of Sales, With An Expected Effective Tax Rate Of 25% For Next Year And Beyond.

Sun Pharma: Reports U.S. Formulation Sales At $459 Million, Down 1.1%.

 22 May 2026 02:48 PM

Sun Pharma: Reports U.S. Formulation Sales At $459 Million, Down 1.1%.

SUN PHARMACEUTICAL INDUSTRIES: Q4 CONS NET PROFIT 27B RUPEES VS 21.5B (YOY); EST 28B

 22 May 2026 02:45 PM

SUN PHARMACEUTICAL INDUSTRIES: Q4 CONS NET PROFIT 27B RUPEES VS 21.5B (YOY); EST 28B

SUN PHARMACEUTICAL INDUSTRIES: Q4 EBITDA 39.54B RUPEES VS 37.16B (YOY) || Q4 EBITDA MARGIN 27.1% VS 28.68% (YOY) - AS PER STATEMENT

 22 May 2026 02:45 PM

SUN PHARMACEUTICAL INDUSTRIES: Q4 EBITDA 39.54B RUPEES VS 37.16B (YOY) || Q4 EBITDA MARGIN 27.1% VS 28.68% (YOY) - AS PER STATEMENT

SUN PHARMACEUTICAL INDUSTRIES: Q4 REVENUE 146B RUPEES VS 129.59B (YOY)

 22 May 2026 02:46 PM

SUN PHARMACEUTICAL INDUSTRIES: Q4 REVENUE 146B RUPEES VS 129.59B (YOY)

Sun Pharma: May Face Increased Scrutiny Due To CDSCO's Action Against Cosmetic Injectables.

 21 May 2026 10:46 AM

Sun Pharma: May Face Increased Scrutiny Due To CDSCO's Action Against Cosmetic Injectables.